ScreenerHero

KLDOKaleido Biosciences, Inc.

NAS · US · Healthcare · Biotechnology · kaleido.com
0.0001USD0.00%Mkt Cap: 4262 $P/E: —

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative coliti…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap4.26K $
Enterprise Value-16.78M $
Revenue (TTM)1.10M $
Gross Profit-66.70M $
Net Income (TTM)-90.29M $
Revenue/Share0.0260 USD
Last Price0.0001 USD
Fiscal Year EndDec 2021
MR QuarterDec 2021
Employees76
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.00
PEG—
EV/EBITDA0.20
EV/Revenue-15.20
P/S0.00
P/B0.00
EPS (TTM)-2.16
EPS (Forward)-0.85
52W Range
0.00000% of range0.1900
52W High0.1900 USD
52W Low0.0000 USD
Profitability
Gross Margin0.00%
Oper. Margin-3974.39%
EBITDA Margin0.00%
Profit Margin-8178.26%
ROE-851.21%
ROA-180.08%
Growth
Revenue Growth102.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-77.09M $
CapEx (TTM)1.13M $
FCF Margin-4168.84%
FCF Yield-1079868.61%
Net Debt-16.78M $
Net Debt/EBITDA0.20
Balance Sheet
Debt/Equity2.05
Current Ratio1.43
Quick Ratio1.33
Book Value/Sh0.2490 USD
Cash/Share0.9030 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.42.62M
Float42.45M
Insiders0.00%
Institutions0.06%
Short Interest
Short Ratio29.3d
Short % Float14.19%
Short % Out.5.49%
Shares Short2.34M
Short (prev mo.)2.16M
Technical
SMA 500.0001 (+3.7%)
SMA 2000.0001 (-21.9%)
Beta40.04
S&P 52W Chg18.16%
Avg Vol (30d)570
Avg Vol (10d)931
Technical Indicators
RSI (14)52.6
MACD0.0000
MACD Signal-0.0000
MACD Hist.+0.0000
BB Upper0.0001 USD
BB Middle0.0001 USD
BB Lower0.0000 USD
BB Width121.76%
ATR (14)0.0000 USD
Vol Ratio (20d)0.27x